Free Trial
ASX:MXC

Argent BioPharma (MXC) Stock Price, News & Analysis

Argent BioPharma logo

About Argent BioPharma Stock (ASX:MXC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.16 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
3.70%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MXC Stock News Headlines

[ATTENTION] This Crypto Rocket Is About Launch…
Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.
Argent BioPharma’s Strategic Moves and Collaboration
Argent Biopharma Lists New Shares on ASX
Argent BioPharma Issues New Shares Amidst Strategic Growth
Argent BioPharma Secures Funding for Drug Development
Co-Founder of Argent BioPharma Picks Up 3,721% More Stock
See More Headlines

MXC Stock Analysis - Frequently Asked Questions

Argent BioPharma Limited (ASX:MXC) issued its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include NVIDIA (NVDA), Walt Disney (DIS), Grayscale Bitcoin Trust ETF (GBTC), Tesla (TSLA), AbbVie (ABBV), Advanced Micro Devices (AMD) and AstraZeneca (AZN).

Company Calendar

Last Earnings
2/28/2019
Today
7/16/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:MXC
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($3.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$17.02 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-307.40%
Return on Assets
-58.96%

Debt

Debt-to-Equity Ratio
1,436.12
Current Ratio
0.75
Quick Ratio
0.50

Sales & Book Value

Annual Sales
A$1.32 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
25.00
Book Value
A$0.04 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
43,850,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.03
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (ASX:MXC) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners